Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya

Fig. 1

Age-stratified population immunity profile. Estimated age-stratified proportion of the Kilifi County population who were immune to measles infection in August 2019 from data. Antibody concentrations ≥ 0.12 IU/ml were defined as protective. Confidence bounds displayed (in red) are the 95% quantiles of a nonparametric bootstrap that is used to propagate uncertainty into the modelling framework. MCV1 is recommended to be administered at 9 months as per the Kenyan immunisation schedule and MCV2 from 18 months

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us